Monthly Archives: April 2022

An episode of a CNN show about psychedelic drug treatments sent Spring resident Katy Parr on a quest.

Psychedelic healing was the topic on host Lisa Lings This Is Life series on CNN.

The story centered on three individuals: one who used psilocybin on his own, another who tried ketamine with a psychiatrist and a third who had treatments of methylenedioxymethamphetamine (commonly known as Molly or Ectasy) with the nonprofit Multidisciplinary Association for Psychedelic Studies.

Parr was so intrigued that sometimes the show became too overwhelming to watch.

I had to stop several times and cry, she recalled.

Parr has experienced depressive symptoms since adolescence and began therapy at 25. She has anxiety, major depressive disorder and complex post-traumatic stress disorder.

In the past, Parr has been prescribed several different selective serotonin reuptake inhibitors (SSRIs), a class of drugs used as antidepressants. The experience only set her back, she said.

Therapy, however, has been essential for her treatment. The idea of coupling it with psychedelic healing, as she saw on CNN, seemed promising.

On HoustonChronicle.com: Clinic Field Trip Health brings ketamine-based therapy to depression treatment

Parr called her therapist, who replied, I think youd be an incredible candidate for this.

Chloe Chew gives a tour Friday, March 11, 2022, at Field Trip Health in Houston.

Her therapist was actually in the midst of training with MAPS but not yet able to prescribe anything.

She recommended Field Trip, Parr said. She knew that they had a new office here, right in our backyard.

Field Trip Health Houston at 4310 Westheimer, opened in May. The company, which now has 12 locations globally, launched in Canada in 2019.

Field Trip Health says on its website that clients using ketamine-assisted psychotherapy report 92 percent improvement with anxiety and 89 percent with depression one month after treatment.

Parrs treatment began at the end of September.

During the first psychedelic exploration session, Parr received two small doses of ketamine and was monitored for her reaction.

This appointment sets the stage for the correct dosage moving forward. Its also a time for psychotherapists to gauge how the body will respond to ketamine.

The goal is to get you into a psychedelic space, Parr said. Thats where the healing happens.

She had six more psychedelic explorations, and during each, her dosage increased.

Youre in an enclosed room in a zero-gravity chair that reclines, Parr said. She had a weighted blanket, eye shades and headphones pumping out a curated playlist.

Field Trip Health, photographed Friday, March 11, 2022, in Houston.

Her guide, psychotherapist Bobbie Russell, was in the room and there to help if she picked up on any signs of distress.

The psychedelic explorations are paired with full integration appointments, when Russell and Parr could discuss what happened.

It helped me understand what all of this was about, Parr said.

Renew Houston: Get the latest wellness news delivered to your inbox

She scheduled three weeks with six explorations and three integrations. She went from feeling high at the lower dosages to having a full psychedelic experience later on.

Its almost like youre jerked into a different reality, she said.

The experience was cathartic.

This medicine is bringing you on a journey, Parr said.

Russell was drawn to merging psychedelics with therapy after reading studies of how effective the option has been.

I knew my clients deserved the absolute best treatments we could give them, she said.

Field Trip Health sources ketamine from licensed medical suppliers and employs a trained team of health professionals to support treatment. All treatments are completed with supervision and on-going monitoring to ensure safety.

Russell said the treatment is an option for individuals with depression, anxiety, PTSD or chronic pain.

I want them to know that there is hope, she said.

Many of her clients have treatment-resistant depression. Theyve tried everything, but they dont have symptom reduction, Russell said.

Bobbie Russells shoes sit next to crystals Wednesday, March 16, 2022, at Field Trip Health in Houston.

With ketamine, she has seen a change in her patients. She said that the treatment, which is short term and lasts four to six weeks, is about 80 percent effective.

Its safe, she said. Its medically monitored. Its evidence-based and its effective.

Therapists are also trained to deal with trauma and to work with veterans.

A common concern, Russell said, is that ketamine will be addictive. Another is that the drug alone will treat a symptom. Neither is true, Russell said.

Its the medicine and psychology working together, she said. Its not the drug itself.

Russell said talk therapy sessions help patients integrate the psychedelic experiences to create long-lasting, positive outcomes.

One of the main lenses she uses for therapy is the internal family system, which explores an individuals subpersonalities in order for them to better understand identity.

Russell uses the Pixar film Inside Out to explain the concept. The main character Riley is faced with a move across the country, and her emotions guide her on the journey.

Crystals and coloring books, photographed Friday, March 11, 2022, at Field Trip Health in Houston.

All of these parts of herself have different feelings and ideas of how Riley should react, Russell said. Their views are informed by life experiences. Sometimes, they can be our worst critics, but they are there to guide us and keep us safe.

By building understanding of these aspects, clients can better spot their triggers and guide their own responses.

Pairing the therapy with psychedelics holds immense promise for patients, Russell said.

It empowers them to make informed changes in their behavior and reaction to stress, she said.

For Parr, the internal family systems approach was a game changer.

Its helped a lot with how I speak to myself, like moving past negative self talk, she said.

And when it came to changing her reaction to stress, Parr put that to the test, shortly after completing her treatment with Field Trip Health.

About a week after her last individual session, she went through a divorce. She said the therapy helped her take in stride what, in the past, would have been impossible to handle.

I think this happened at just the right time of my life, Parr said. I was able to accelerate the therapy in that psychedelic space. Out of that session I got so much.

Some clients come into Field Trip Health skeptical about the treatment, Russell said.

Theyve tried everything and dont believe this is going to work, she said. But theyre out of options.

After a month, they return telling a different story, she said.

Bobbie Russell, a social worker, poses for a portrait Wednesday, March 16, 2022, at Field Trip Health in Houston.

Theyll say, For the first time in my life, I dont have crippling anxiety. For the first time, Im not depressed, she said. And that is why I get up every day to go to work. My clients say they feel better.

That doesnt mean they are cured, Russell added. But their baseline is better, she said. They leave treatment with hope, with a renewed view of life and with new skills.

Parr, for instance, said she will face depressive symptoms for the rest of her life. In the past, that realization could make her feel hopeless, like depression was lurking on the horizon.

But the ketamine treatments, in conjunction with her usual therapist, have given her a different outlook.

It helped me focus on the fact that its not always going to be like this, she said. Even when I dont have access to joy in those moments, I know it will be available to me in the future.

She added, The work that Ive done is helping me change my relationship with depression and see it more as a teacher in my life instead of a monster always following me around.

Peyton is a Houston-based freelance writer.

Excerpt from:

Field Trip Health Houston's psychedelic healing with ketamine helps patient with depressive anxiety - Houston Chronicle

Californias K-12 Enrollment Drops Again. We Ask Local Districts What Theyre Seeing

CA School Enrollment 4.13.22

Californias K-12 enrollment has dropped for the fifth year in a row, and the California Department of Education says the trend is projected to continue. When comparing this academic year to the previous one, California public schools lost 110,000 students, a steeper drop than we saw before the pandemic, when declines were driven largely by demographic shifts due to housing affordability. Most California public schools are funded based on enrollment and attendance, so the enrollment drop could have big implications for districts bottom lines.

Today on AirTalk, we discuss these drastic changes to enrollment, whats driving them, and how the trend could possibly be reversed with dean of the USC Rossier School of Education Pedro Noguera, San Bernardino City Unified School District associate superintendent Harold Sullins, and El Monte City School District superintendent Maribel Garcia.

MLB Bets Big On Streaming With Apple TV Deal -- Will It Drive In New Fans Who Turn Into Subscribers?

MLB and Streaming 4.13.22

For decades big money in baseball broadcast rights has been traditional cable television, but now as streamers proliferate, Major League Baseball is stepping up to bat with a major streamer who just won Best Picture at the Oscars and also features one of the most beloved and acclaimed series on streaming TV.

Last month, MLB and Apple TV announced a deal to broadcast a Friday Night Baseball doubleheader on Apple TV. Forbes reported that sources close to the deal said it is worth $85 million a year, and Apple says access to the games is free until June. Major League Baseball also signed a two year deal, per Forbes, to broadcast Sunday games on NBCUniversals streamer, Peacock. For baseball, a sport that desperately needs to reach new fans, its a bet that theyll get more eyeballs on a national scale and that fans will follow their favorite teams onto the streaming platforms. And for the streamers, its a bet that those people following their teams to the platforms will be first-time users of the platforms who turn into subscribers when they begin exploring other content.

Today on AirTalk, Los Angeles Times baseball writer Bill Shaikin calls in to talk about his reporting on why Major League Baseball thinks this will be a win for both the league and the streamers who will now carry games, and why both sides are betting fans will like it too.

Baseballs Rebels: The Dissenters, Radicals, Mavericks And Trailblazers That Changed The Game

Peter Dreier Baseball Book 4.13.22

The history of baseball is rife with stories of people who pushed boundaries, blazed trails and shattered glass ceilings. Jackie Robinson being the first Black man to play in the Majors is probably the most well-known, but the effort to desegregate baseball that led to Jackie even being in a position to make history began well before the Pasadena native first set foot on the diamond for the Brooklyn Dodgers in 1947. And as Occidental College Professor of Politics Peter Dreier writes in his new books Baseball Rebels: The Players, People, and Social Movements That Shook Up the Game and Changed America and Major League Rebels: Baseball Battles over Workers' Rights and American Empire, Jackies story is just one chapter, albeit an incredibly important one, in the history of changemakers in baseball, whose impacts have spanned and still span across labor, gender and sexuality. Just this past week, Rachel Balkovec became the first woman to ever manage an MLB-affiliated team when she won her debut game managing the Tampa Tarpons, a minor league affiliate of the New York Yankees.

Today on AirTalk, Professor Dreier returns to the show to talk about his, both of which explore figures in baseball from players to managers to journalists who challenged the status quo, sometimes at the cost of professional success or even their career. Hell also talk about how we see some of these themes continue to play out in 2022 after Major League Baseballs season hung in the balance for a period of time in February and March during the labor lockout.

Professor Dreier will be talking about his books coming up next week on Tuesday, April 19th, at 6:00 p.m. in a virtual event presented by Vromans Bookstore. Registration is free and you can sign up to receive the link to the virtual discussion here.

Mental Health Week: What One Doctor Says Americas Mental Health System Is Missing, And How To Fix It

Mental Health Healing Books 4.13.22

In 2015, Dr. Thomas Insel, at that time, head of the National Institute of Mental Health, was giving a talk about stem cell studies of neurons in schizophrenia, when the father of a 23-year-old man with schizophrenia stood up and said, Our house is on fire and you're talking about the chemistry of the paint." The interaction changed the trajectory of Insels professional life. In his new book, he argues that while science has made tremendous insights to understand mental illness and develop better tools for diagnosis and treatment, the U.S. mental health system hasnt done enough to help ordinary Americans.

Today on AirTalk, Larry speaks with Dr. Thomas Insel, psychiatrist, neuroscientist and former head of the National Institute of Mental Health about his new book, Healing: Our Path from Mental Illness to Mental Health, and how Americas mental health care systems can pivot to better address the current mental health crisis.

If you or a loved one needs help, call the National Suicide Prevention Lifeline at 1-800-273-8255. Los Angeles County maintains a 24-hour bilingual hotline at 800-854-7771.

Mental Health Week: Magnetic Stimulation, Psychedelics and Tai Chi How Treatments For Anxiety And Depression Are Growing

Mental Health Treatment 4.13.22

For many people, the burdens of mental illness are a daily struggle that the pandemic has only intensified. According to the World Health Organization, during the first year of the pandemic, rates of anxiety and depression increased by 25% worldwide. That is a massive jump. Another study found 33% of adults in the U.S. experienced elevated depressive symptoms during the first year of the pandemic. For decades, those suffering from depression have benefited from SSRIs, selective serotonin reuptake inhibitors, like prozac and zoloft among many others. But taking and prescribing these medications is not that simple. People become treatment-resistant over time, and many mood disorders can be difficult to diagnose, with no biological markers clearly indicating whether someone has bi-polar depression or a substance abuse disorder, for example. This is one of the reasons that researchers have been developing new forms of treatments for anxiety and depression that are non-invasive, long-lasting, and with minimal side-effects.

Today on AirTalk, were joined by geriatric psychiatrist and professor of psychiatry at UCLA Helen Lavretsky, professor of psychiatry at Stanford University and director of the Brain Stimulation Lab Nolan Williams, and professor of psychiatry at Johns Hopkins and researcher at the Johns Hopkins Center for Psychedelic and Consciousness Research, Albert Garcia-Romeu to talk about how mental health treatments are evolving and how they soon might be made more widely available to those in need.

Read the original post:

Mental Health Week: Magnetic Stimulation, Psychedelics and Tai Chi How Treatments For Anxiety And Depression Are Growing - KPCC

Everyone wants a good nights sleep. There are multiple over-the-counter pharmaceuticals for sleep assistance, most with side effects such as dizziness and headaches, and other physical unpleasantries.

Cannabis has seemingly cornered the sleep market for those exploring alternative sleep strategies with a plant-based option, as more CBD and THC products are marketed and sold specifically for help with sleep. For example, Plus Products (OTC: PLPRF) has two products specifically marketed toward aiding sleep with varying levels of THC included.

The thinking is that yes, cannabis will certainly make you sleepy, specifically any indica strain. But is it helpful for your psychological well-being and your sleep/wake cycle? Can you keep taking it for sleep? Data to prove those points is a bit dodgyresearch on sleep and cannabis is in its infancy, one study added, and has yielded mixed results.

While studies indicate that cannabis may hold promise for REM sleep behavior disorder and excessive daytime sleepiness, and may reduce nightmares associated with PTSD, the study of sleep and cannabis has been plagued by error and bias, according to one study, with no hard and fast conclusions drawn except to note that there does not appear to be a consistent effect on total sleep time. These results are consistent with one interpretation that cannabis is typically not beneficial to sleep except among medicinal cannabis users who are identified by the presence of pre-existing sleep interrupting symptoms such as pain, the study concluded.

Another study found that cannabis helped people who had chronic pain issues sleep, but that use of cannabis overtime did not have the same effect. There is even a concern that cannabis consumption is associated with an increased likelihood of developing bipolar disorder, perhaps because of interactions of THC with sleep/wake circadian rhythm cycles.

Sleep disturbance is strongly associated with the development and maintenance of many common psychological disorders, including depression. Researchers have discovered that the need for sleep increases more slowly during wakefulness and so is chronically low in depressed patients. It is unclear whether sleep changes in depression represent disease symptoms or adaptive mechanisms to help handle the depressive state. Acute sleep deprivation oddly enough creates an anti-depressive effect that typically relapses after subsequent sleep occurs, according to research. There is a clear need for a large scale, longitudinal and well-controlled study on the specific effects of cannabinoids on sleep, a study concluded.

Now researchers are looking at psychedelics as a potential aid for sleeping. In a recent study published in Translational Psychiatry in February 2022, electrophysiological recordings were collected from mice to track sleep-wake architecture and cortical activity after psilocin injection. The mice had delayed REM sleep onset, and no long-term changes in sleep-wake quantity were found.

Psilocin-affected mice spent a significant amount of time in their nests, adopting a posture compatible with sleep, but still apparently awake according to electrophysiological measurements. Rest in these animals was frequently disturbed by small body movements, such as stretches and readjustments of posture, and often the eyes remained open even while motionless.

What researchers concluded is that the modulation of REM sleep is a core mechanism of the psychological benefits of psychedelics, although it remains possible that the underlying brain activity of REM sleep is affected in a more subtle way.

Psychedelic drugs such as psilocybin provide a novel approach to studying the basic science of sleep regulation, offering a means to manipulate the content of wakefulness and associated brain dynamics, the February 2022 study concurred. Psychedelic stimulation offers important advantages compared to other manipulations of waking brain activities because of its relative simplicity, physiological validity, translatability to humans, and comprehensibility in terms of the associated conscious experience.

So, bottom line, the jury is out on how helpful psychedelics is for sleep control. Research with psychedelics and sleep essentially is no further along than similar research with cannabis for sleep.

From the clinical perspective, sleep represents an overlooked aspect of physiology to understanding how psychedelic-mediated mechanisms yield psychological benefits, according to the February, 2022 study.

But this study using psilocybin for sleep is just another way that psychedelics are helping scientists understand the full range of its benefits. Although many essential questions remain, a consistent picture of psychedelic biology is gradually forming, carrying the great potential to inform neuroscience in areas spanning basic neurobiology to clinical practice.

Post Views:756

Read more:

Psychedelics Want To Win Over The Sleep Aid Market - Green Market Report

NEW YORK, April 13, 2022 /PRNewswire/ -- Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Blumentech S.L. ("Blumentech") to acquire Blumentech's full patent portfolio and accompanying data,which includes multiple groundbreaking discoveries by the late Dr. Jordi Riba Serrano, a renown ethno-pharmacologist and pioneer of psychedelics research.

Widely admired for his trailblazing work in the space, Dr. Riba was the first to conduct a placebo-controlled study of ayahuasca in 1999, and published extensively on the ability of the molecule DMT to induce neurogenesis. His findings demonstrated novel ways to maintain the therapeutic and neurogenic benefit of psychedelic compounds while also reducing potential side effects and increasing the potential for use across a much wider population of patients.

During his time as a senior researcher at the Sant Pau Biomedical Research Institute in Barcelona, Dr. Riba founded Blumentech in 2017 as a spinout to advance his research and further explore these new possibilities and applications for psychedelics. That same year he was featured alongside Elon Musk and Kamala Harris on Rolling Stone's list of "25 People Shaping the Future," highlighting the visionaries who are "changing (and maybe saving) the world one brilliant idea at a time."

Since Dr. Riba's passing in 2020, his son Marc Riba has stepped in as a director at Blumentech to keep the work moving ahead. "My purpose is to continue my father's legacy. His vision was to use his research to find solutions for the millions of people suffering from mental and neurological illnesses," stated Marc, "Thanks to our great team at Blumentech, led by Gerard de Lucas, we were able to protect and expand my father's intellectual property. Now we are happy to partner with the team at Terran, who we know will be able to ensure his important work continues and take his vision to the next level. We have been impressed by their team, IP, portfolio, and novel approach to the space, and we have faith they will be successful in delivering new therapeutic options to patients in need."

Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug discovery program.

Dr. Sam Clark, CEO of Terran commented "We are honored to partner with Blumentech and advance these assets as quickly as possible. Dr. Riba truly opened the door to this entire field of research, and we hope we too can open doors for patients with these innovative approaches."

The deal also included data and patent rights assigned and licensed from several academic institutions in Spain, including: Fundaci Institut de Recerca de l'Hospital de La Santa Creu i Sant Pau (FIRHSCSP), Universidad Autnoma de Madrid (UAM), State Agency Consejo Superior de Investigaciones Cientificas M.P (CSIC), and Consorcio Centro de Investigacin Biomdica en Red (CIBER).

About Terran Biosciences, Inc.

Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing of number of late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact

Investor Relations:[emailprotected]

Media:[emailprotected]

SOURCE Terran Biosciences, Inc.

See the article here:

Terran Biosciences and Blumentech SL announce the acquisition of a patent portfolio covering the groundbreaking discoveries of prominent psychedelics...

Federally-licensed research lab received additional 56 Research Exemption to acquire psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc.

VANCOUVER, BC, April 13, 2022 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Delic Labs, received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B. Additionally, Delic Labs has received a Health Canada 56 exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs' latest exemptions enable the Company to develop innovative analytical methods for psychedelic research.

Delic Logo (CNW Group/Delic Holdings Inc.)

Last year, the lab also applied for a Dealer's License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes. Securing a Dealer's License to accompany its existing research exemptions would cement Delic Labs' position as the leader in psychedelic safety testing. The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.

Delic Labs is the engine of innovation for Delic Corp, conducting research and developing new product lines and IP. The Company's latest foray into psilocybin research reaffirms its commitment to advancing extraction methods, analytical testing and chemical process development.

"Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds," said Dr. Markus Roggen, co-founder of Delic Labs. "Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our Dealer's License is secured."

Story continues

Founded by award-winning chemist, Dr. Roggen, and UBC Professor, Dr. Glenn Sammis, Delic Labs supports the psychedelic and cannabis industry with high precision chemical analytics, metabolomic identification and process optimization. Delic Labs is one of a handful of licensed psilocybin research labs in Canada and has an strategic plan to develop a suite of novel compounds and delivery methods for the industry. Delic Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world.

About Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.)

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/delic-labs-receives-health-canada-56-exemption-to-conduct-research-on-mdma-lsd-and-other-psychedelic-compounds-301524469.html

SOURCE Delic Holdings Inc.

The rest is here:

Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds - Yahoo Finance

By Natashia Gebre-Zion

In 2018, the Farm Bill removed hemp from the Controlled Substances Act, making hemp and cannabidiol (CBD) legal in all 50 states.

CBD can be found in both body products and in oils; however, one of the biggest uses of CBD is in food and beverage products.

Dr. Sang Park, a senior scientist with the Institute of Cannabis Research at CSU Pueblo, shared his view on using cannabis in food.

Seed oil doesnt have any THC; you dont have to worry about ingesting any THC from seed oil products, he said. It is very clean and safe to use in food production.

One of the biggest debates going on currently, is the health benefits of cannabis products. Dr. Park was another big supporter of these benefits, as he went into detail about different benefits he is seeing with the use of CBD.

[Cannabis] is not synthetic, Its a natural product, Park said. Lets say you have a headache or migraine, you can go to the hospital and they just prescribe medicine, but you dont have to buy that medicine.

You can go to a natural grocery store and grab a CBD-infused medicine and save a lot of money, and its from nature so it doesnt have many of the side effects.

Park said CBD is also a safe alternative for children who are experiencing physical health problems that are impacting their nutrition.

[CBD] is a good alternative medicine for epilepsy patience, if you put some under the tongue then it can stop seizures, Parks said.

He also discussed that CBD is being used to calm the nervous systems. A lot of cancer patients use CBD while they are receiving chemotherapy treatments. Normally, individuals going through chemotherapy, experience nausea and have a hard time keeping their food down. Ultimately, this causes a delayed recovery, because individuals are not getting the nutrition that they need.

CBD-infused products, like this brand of watermelon-flavored water, are growing in popularity at health food stores. [Today photo/Natashia Gebre-Zion]Many parents who have neurodivergent children have turned to CBD products, including food and beverages, as an alternative to Ritalin to assist in calming the nervous system.

CBD works wonders for my son. He has autism (ASD), and it has been a game changer, said Laci Pinckney, a mom from New York. Our son used to take [prescription] medications. He no longer uses any of those.

With the rise of social media, there has been an increase of awareness surrounding alternative medicine, that doesnt just revolve around cannabis, but also psychedelics.

Nathan Sepeda, a research data specialist at The John Hopkins University School of Medicine, discussed how John Hopkins is currently gathering research about psychedelics. Sepeda explained that psychedelics are being tested to help with mental disorders like anxiety, depression and PTSD.

I dont think psychedelics will ever replace traditional medicine, but it will be another tool in the toolkit There are a large portion of people that find that antidepressants dont work, and for those people maybe something like psychedelics will help, Sepeda said.

Parks research surrounding cannabis and CBD is another tool in the toolkit, like Sepeda mentioned. CBD is being used to help with anxiety, depression and physical pain.

Though alternative medicine is a positive alternative, Park did share his concerns with CBD.

Too much is bad, he said. It can cause liver damage, and because people dont know how often to take CBD oil it can cause a lot of abdominal pain.

I have spoken with ER doctors, and they reported that there are a lot of patients screaming because of the abdominal pain, and they are realizing these are the people over-using cannabis products.

Sepeda also shared his concerns with psychedelic research.

In terms of the research, we are really excited about psychedelics and their potential and the different avenues that psychedelics are being tested for, Sepeda said. Some concerns are the narrative that gets adopted by the mainstream. As the narrative is being published more and more, the narrative is shifting and being described as a cure-all, but that is not always the case and there are people who dont experience the benefits. There should be caution about how these treatments are being described.

Read the original post:

Experts discuss the intersections of cannabis, health and food - CSU Pueblo Today